Understanding the differences between experimental immuno-oncology models, and where each fits best into drug development programs, is an essential part of IO research. However, model-representativeness amongst correctly choosing or progressing through, in vitro, syngeneic, PDX, and humanised drug target models still represents major issues during preclinical development.
Returning for its 3rd year, Tumour Models San Francisco remains dedicated to exploring the continued application and evolution of cancer immunotherapy models to enhance the translational success of immuno-oncology therapies from bench to patient.
Sitting at the interface of innovation in model development and therapeutic application, the event merges strategic perspectives with new insights from pioneering biotech and pharmaceutical organizations into emerging therapeutic programmes.
Dive into how they’ve been utilizing emerging and classical model systems to support early-late stage decision making for the translation of their IO therapeutics. Find out more here.
Highlights from Tumour Models London 2017